Insider Trading Arrangements

3 Months Ended

Jun. 30, 2024

Item 5.

Other Information.

Insider Trading Arrangements

Prior to May 1, 2024 all of our officers, as defined in Rule 16a-1(f) under the Exchange Act, and our directors had engaged in a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408 of Regulation S-K. When our common stock was suspended from trading on the Nasdaq Capital Market beginning on May 2, 2024, our transfer agent terminated each of these arrangements. Currently, our policy with regard to insider trading is, and will remain, that trading in our common stock by our officers and directors is strictly limited to non-blackout periods and any other time when no officer or director is aware of any material non-public information concerning the Company. At such time when it is practical to do so, we will encourage our officers, directors and any other insiders to enter into new Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements.

All directors and officers

Trading Arrangements, by Individual

Rule 10b5-1 Arrangement Terminated

true

Non-Rule 10b5-1 Arrangement Terminated

true

Termination Date

May 1, 2024

PaxMedica, Inc. 10-Q